BS_PN2CE34A
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- overall_survival_months
- 20.49934296977661
- age_years
- 5.362
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.298
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.204
- HYPOXIA+0.174
- MYC_TARGETS_V2+0.152
- KRAS_SIGNALING_DN+0.132
- COAGULATION+0.104
- APICAL_JUNCTION+0.085
- P53_PATHWAY+0.077
- IL2_STAT5_SIGNALING+0.065
- ALLOGRAFT_REJECTION+0.053
Top 10 suppressed
- PROTEIN_SECRETION-0.498
- MYC_TARGETS_V1-0.478
- ANDROGEN_RESPONSE-0.440
- MTORC1_SIGNALING-0.413
- E2F_TARGETS-0.404
- OXIDATIVE_PHOSPHORYLATION-0.383
- G2M_CHECKPOINT-0.370
- PANCREAS_BETA_CELLS-0.316
- CHOLESTEROL_HOMEOSTASIS-0.307
- HEDGEHOG_SIGNALING-0.262
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R33 | — | — | 0.817 |
| 2 | BS_G5QBBHDV | low-grade glioma | — | 0.802 |
| 3 | MNG779 | — | — | 0.792 |
| 4 | MNG656 | — | — | 0.792 |
| 5 | MNG1087 | — | — | 0.788 |
| 6 | SRR8942953 | — | — | 0.782 |
| 7 | BS_77317DY4 | Med | Medulloblastoma | 0.774 |
| 8 | MNG655 | — | — | 0.768 |
| 9 | BS_0XEG6SNV | Supratentorial Ependymoma | — | 0.761 |
| 10 | R76 | — | — | 0.755 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.298 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.204 | Inavolisib | — uncovered |
| HYPOXIA | 0.174 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.152 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.132 | Remibrutinib | — uncovered |
| COAGULATION | 0.104 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.085 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.077 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.065 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.053 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.044 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.016 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.012 | Inavolisib | — uncovered |